Machine learning fuels personalised cancer medicine

by IRB Barcelona - Instituto de Investigación Biomédica

The Biomedical Genomics laboratory at IRB Barcelona has developed a computational tool that identifies cancer driver mutations for each tumour type. This and other developments produced by the same l...

Read more

IDIBELL and ICO participate in the discovery of a weakness that could be used to treat defective cancers for SMARCA4

by Hospital Universitari de Bellvitge

The study suggests that tumors with a genetically inactivated form of the chromatin remodeling protein SMARCA4 are highly sensitive to inhibitors of the KDM6 family of histone demethylases.

Read more

Scientists from the ibs.GRANADA show that the risk of developing acute myeloid leukemia depends on the presence of genetic variations in genes of the immune system

by Instituto de Investigación Biosanitaria - Ibs Granada

The Genetics of Malignant Hemopathies research group at ibs.GRANADA has shown that certain variations in genes of the immune system influence the risk of developing acute myeloid leukemia. These alter...

Read more

Eight CSIC biomedical projects receive 6.5 million euros from the CaixaResearch aid program

by CSIC - Centro Superior de Investigaciones Científicas

Eight researches led by or with the participation of scientists from the Spanish National Research Council (CSIC) have been selected by the “la Caixa” Foundation among the 30 projects of the Caixa...

Read more

Cancer and dementia research projects funded by the 'la Caixa' Foundation

by Centre for Genomic Regulation

​The “la Caixa” Foundation has funded two research projects at the Centre for Genomic Regulation (CRG) which aim to identify new therapeutic targets for cancer and develop new prevention strateg...

Read more

​ To die or not to die in response to stress, a decision regulated by MK2 protein levels

by IRB Barcelona - Instituto de Investigación Biomédica

Researchers at IRB Barcelona unveil a pathway that determines the fate of cells in response to stress conditions and identify an important mechanism that recovers cell balance.

Read more

PNAS. CNIO researchers clarify the role of the two isoforms of KRAS, the most common oncogene in human cancer

by CNIO - Centro Nacional de Investigaciones Oncológicas

KRAS was one of the first oncogenes to be identified, a few decades ago. It is among the most common drivers of cancer and its mutations can be detected in around 25 per cent of human tumours. The dev...

Read more

Cellular push and pull, a key to the body's response to processes such as cancer

by Fundació Clínic per a la Recerca Biomèdica

Researchers from IDIBAPS, IBEC, UB and CIBERES discover how force dynamics affect cells and living tissues. The results give an insight into the critical mechanical processes that occur in different d...

Read more

A new approach to metastatic melanoma discovered

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

​Combining chemotherapy and BRAF oncogene inhibitors is a very effective strategy for fighting metastatic melanoma, the leading cause of death from skin cancer in the world.

Read more

The immune microenvironment as a driver of disease progression in chronic lymphocytic leukemia

by VHIO

Research led by VHIO investigators represents a step forward in better understanding the underlying mechanisms that drive disease progression in chronic lymphocytic leukemia (CLL).

Read more

Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to Test Cancer Patients for Rare NTRK Mutations in Saudi Arabia

by OncoDNA

OncoDNA, Tamkin Al-Seha Medical and Bayer Saudi Arabia announced today a new partnership to broaden access to Neurotrophic Tyrosine Receptor Kinase (NTRK) biomarker testing and identify patients eligi...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

by Labo'Life

Photos Stream